natgillin/translations-raw huggingface dataset:
Although not statistically significant, the majority of patients demonstrated clinical improvement in secondary endpoints such as number of sites of enthesitis, tender joint count (TJC), swollen joint count (SJC), Pediatric ACR 50 response, and Pediatric ACR 70 response. 
Čeprav ni statistično značilno, je bilo pri večini bolnikov dokazano klinično izboljšanje sekundarnih opazovanih dogodkov, kot so število mest entezitisa, število občutljivih sklepov, število oteklih sklepov, odziv glede na merila Pediatric ARC 50 in Pediatric ARC
• Hold the syringe package and SLOWLY pull the white plunger rod out to 0.1 ml beyond the prescribed dose (For example, if the prescribed dose is 0.5 ml, pull the white plunger rod to 0.6 ml). 
• Držite ovojnino brizge in POČASI potegnite beli nosilec bata ven, tako da je 0,1 ml preko predpisanega odmerka (Če je npr. predpisani odmerek 0,5 ml, potegnite beli nosilec bata do
Study nr-axSpA II was a treatment withdrawal study in active nr-axSpA patients who achieved remission during open-label treatment with Humira. 
Študija nr-axSpA II je bila študija prenehanja zdravljenja pri bolnikih z aktivnim nr-axSpA, ki so med zdravljenjem z zdravilom Humira v odprti fazi zdravljenja dosegli remisijo.
Hold the pre-filled syringe in one hand. 
Napolnjeno injekcijsko brizgo držite v eni roki.
Patients must therefore be monitored closely for infections, including tuberculosis, before, during and after treatment with Humira. 
Bolnike je zato treba pred, med in po zdravljenju z zdravilom Humira natančno kontrolirati glede okužb, vključno s tuberkulozo.
MTX = methotrexate P=0.027, Humira 0.8 mg/kg versus MTX P=0.083, Humira 0.8 mg/kg versus MTX 
PGA: čisto/minimalnoc a MTX = metotreksat b P = 0,027, Humira 0,8 mg/kg v primerjavi z MTX c P = 0,083, Humira 0,8 mg/kg v primerjavi z MTX
There are no clinical trials with Humira in adolescent patients with HS. 
Kliničnih študij z zdravilom Humira pri mladostnikih s HS ni.
Use of anti-tuberculosis prophylaxis treatment should also be considered before the initiation of Humira in patients with several or significant risk factors for tuberculosis despite a negative test for tuberculosis and in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed. 
O uporabi protituberkuloznega profilaktičnega zdravljenja morate pred uvedbo zdravila Humira razmisliti tudi pri bolnikih s hudimi ali pomembnimi faktorji tveganja za tuberkulozo kljub negativnemu testu za tuberkulozo in pri bolnikih z anamnezo latentne ali aktivne tuberkuloze, pri katerih ni mogoče potrditi ustreznega zdravljenja.
Alternatively, if a patient has stopped Humira and signs and symptoms of disease recur, Humira may be re-administered. 
Če bolnik neha uporabljati zdravilo Humira, pa se znaki in simptomi bolezni ponovijo, je mogoče zdravilo Humira znova uvesti.
Slowly push the plunger in to push the air out through the needle. 
Počasi pritiskajte na bat, da iz igle odstranite zrak.
Humira was numerically favoured for the majority of subscores with statistically significant mean differences for general vision, ocular pain, near vision, mental health, and total score in Study UV I, and for general vision and mental health in Study UV II. 
Številke so bile v korist zdravila Humira za večino podrezultatov s statistično značilno povprečno razliko za splošni vid, očesno bolečino, vid na blizu, duševno zdravje in skupen rezultat v študiji UV I, ter za splošni vid in duševno zdravje v študiji UV II.
The safety of Humira in paediatric patients with plaque psoriasis has been assessed for a mean of 13 months. 
Varnost zdravila Humira pri pediatričnih bolnikih s psoriazo v plakih je bila ocenjena za povprečno obdobje 13 mesecev.
The potential risk with the combination of azathioprine or 6-mercaptopurine and Humira should be carefully considered. 
Potrebno je upoštevati potencialno tveganje pri sočasni uporabi azatioprina ali 6-merkaptopurina in zdravila Humira.
Slowly push the plunger all the way in until all of the liquid is injected and the pre-filled syringe is empty. 
Počasi potisnite bat do konca, dokler ne injicirate celotne tekočine in je napolnjena injekcijska brizga prazna.
No clinical data are available on the use of a Humira loading dose in children < 6 years of age (see section 5.2). 
Klinični podatki o uporabi polnilnega odmerka zdravila Humira pri otrocih, mlajših od 6 let, niso na voljo (glejte poglavje 5.2).
Humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. 
Zdravilo Humira je mogoče uporabiti kot monoterapijo v primeru intolerance za metotreksat ali kadar nadaljnje zdravljenje z metotreksatom ni primerno.
The yellow indicator is part of the plunger of the pre-filled pen. 
Rumeni kazalnik je del bata napolnjenega peresnika.
After proper training in injection technique, patients may self-inject with Humira if their physician determines that it is appropriate and with medical follow-up as necessary. 
Bolniki, ki se naučijo pravilnega postopka injiciranja, si zdravilo Humira lahko injicirajo sami, če zdravnik presodi, da je to primerno, in je zagotovljeno ustrezno medicinsko spremljanje.
Humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). 
Zdravilo Humira je mogoče uporabiti kot monoterapijo v primeru intolerance za metotreksat ali kadar nadaljnje zdravljenje z metotreksatom ni primerno (za učinkovitost monoterapije glejte poglavje 5.1).
Of those patients who had a response at Week 8, 47% were in response, 29% were in remission, 41% had mucosal healing, and 20% were in steroid-free remission for ≥ 90 days at Week 52. 
Od bolnikov, ki so bili odzivni v 8. tednu, jih je bilo v 52. tednu 47 % odzivnih, 29 % v remisiji, 41 % je imelo celjenje sluznice in 20 % jih je bilo v remisiji brez steroidov za ≥ 90 dni.
Vision related effects were not numerically in favour of Humira for colour vision in Study UVI and for colour vision, peripheral vision and near vision in Study UV II. 
Učinki povezani z vidom niso bili v korist zdravila Humira v primeru barvnega vida v študiji UV I in v primeru barvnega vida, perifernega vida in vida na blizu v študiji UV II.
• Push plunger to inject solution - it can take from 2 to 5 seconds to empty the syringe 
• Potisnite bat, da boste injicirali raztopino - za izpraznitev brizge utegne biti potrebnih od 2 do 5 sekund.
Patients treated with Humira should be given the Patient Reminder Card. 
Bolniki, ki se zdravijo z zdravilom Humira, morajo dobiti posebno opozorilno kartico za bolnika.
Disease flare criteria were defined as a worsening of  30% from baseline in  3 of 6 Pediatric ACR core criteria,  2 active joints, and improvement of  30% in no more than 1 of the 6 criteria. 
Merila zagona bolezni so bila opredeljena kot poslabšanje ≥ 3 od 6 osnovnih meril Pediatric ACR za ≥ 30 % v primerjavi z izhodiščem, ≥ 2 aktivna sklepa in izboljšanje ne več kot 1 od 6 meril za > 30 %.
No other disease-modifying anti-rheumatic drugs were allowed. 
Uporaba drugih imunomodulirajočih antirevmatičnih zdravil ni bila dovoljena.
Safety of the recommended adalimumab dose in the adolescent HS population is based on cross-indication safety profile of adalimumab in both adults and paediatric patients at similar or more frequent doses (see section 
Varnost priporočenega odmerka adalimumaba pri populaciji mladostnikov s HS temelji na varnostnem profilu indikacij adalimumaba pri odraslih in pediatričnih bolnikih pri podobnih ali pogostejših odmerkih (glejte poglavje 5.2).
• If your child is allergic to adalimumab or any of the other ingredients of this medicine (listed in section 6). 
• če je vaš otrok alergičen na adalimumab ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
19.3% of patients had continued baseline oral antibiotic therapy during the study. 
19,3 % bolnikov je nadaljevalo izhodiščno zdravljenje s peroralnimi antibiotiki.
Reduction in HS-related skin pain was assessed using a Numeric Rating Scale in patients who entered the study with an initial baseline score of 3 or greater on a 11 point scale. 
Zmanjšanje bolečine, povezane s HS, so ocenili s pomočjo numeričme ocenjevalne lestvice pri bolnikih, ki so imeli pri vključitvi v študijo izhodiščni rezultat 3 ali več na 11-stopenjski numerični ocenjevalni lestvici.
• Check that the small black needle cover of the syringe has been removed with the cap 
• Preverite, da je bilo majhno, črno pokrivalo za iglo odstranjeno skupaj s pokrovčkom.
• haematoma (collection of blood outside of blood vessels) 
• hematom (zbiranje krvi izven krvnih žil)
Antibiotics may be continued during treatment with Humira if necessary. 
Humira lahko nadaljujete z antibiotičnim zdravljenjem, če je potrebno.
Do not use the pre-filled syringe and call your doctor or pharmacist if the 
Ne uporabite napolnjene injekcijske brizge in pokličite zdravnika ali farmacevta, če
Psoriasis Study I (REVEAL) evaluated 1,212 patients within three treatment periods. 
Študija pri psoriazi I (REVEAL) je ocenila 1212 bolnikov v treh obdobjih zdravljenja.
If you have active tuberculosis, do not use Humira. 
Če imate aktivno tuberkulozo, ne uporabljajte zdravila
PASI 75 PGA: Clear/minimal a 
PGA: čisto/minimalno
Patients participating in all Phase 2 and Phase 3 psoriasis studies were eligible to enrol into an open-label extension trial, where Humira was given for at least an additional 108 weeks. 
Bolniki, ki so sodelovali v študijah psoriaze 2. in 3. faze, so bili lahko vključeni v odprto podaljšano preskušanje, v katerem so zdravilo Humira prejemali vsaj še dodatnih 108 tednov.
• Your doctor should test your child for HBV. 
• Zdravnik mora vašega otroka testirati na HBV.
Disease-related hospitalisations and surgeries were statistically significantly reduced with adalimumab compared with placebo at Week 56. 
Z boleznijo povezane hospitalizacije in kirurški posegi so bili statistično pomembno zmanjšani pri adalimumabu v primerjavi s placebom v 56. tednu.
The corresponding proportions of patients with no radiographic progression were 31.3%, 23.7% and 36.7% respectively. 
Ustrezni deleži bolnikov, ki niso imeli radiografskih znakov napredovanja, so bili 31.3 %, 23,7 % oz. 36,7 %.
• Set up the following items on a clean surface, DO NOTtake them out of their individual packaging yet. 
• Na čisto površino pripravite sledeče enote zdravila in jih NE JEMLJITE iz njihove posamezne ovojnine:
Humira Δ Censored 
Humira Δ anonimizirano
HR a CI 95% for HR 
RTa IZ 95 % za RTa
In RA study III, most subjects who achieved improvement in physical function and continued treatment maintained improvement through Week 520 (120 months) of open-label treatment. 
V študiji revmatoidnega artritisa III se je pri večini bolnikov, ki so dosegli izboljšanje telesne funkcije in so nadaljevali zdravljenje, to izboljšanje ohranilo vseskozi do 520. tedna (120. meseca) odprte faze zdravljenja.
Humira demonstrated a treatment benefit in nail psoriasis patients with different extents of skin involvement (BSA≥10% (60% of patients) and BSA<10% and ≥5% (40% of patients)). 
Zdravilo Humira je pokazalo terapevtsko korist pri bolnikih s psoriazo nohtov z različnim obsegom prizadetosti kože (telesna površina ≥ 10 % (60 % bolnikov) in telesna površina < 10 % in ≥ 5 % (40 % bolnikov)).
There is a window on each side of the pen through which you can see the Humira solution inside the syringe. 
Na obeh straneh peresnika je okence; skozi okenci lahko vidite raztopino zdravila Humira v notranjosti brizge.
A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE 
A. IZDELOVALEC (IZDELOVALCI) BIOLOŠKE UČINKOVINE (UČINKOVIN) IN IZDELOVALEC (IZDELOVALCI), ODGOVOREN (ODGOVORNI) ZA SPROŠČANJE
Throw the needle cover away. 
Pokrovček igle zavrzite.
The safety and efficacy of Humira in children aged 4-17 years have not yet been established. 
Varnost in učinkovitost zdravila Humira pri otrocih, starih 4-17 let, ni bila potrjena.
How to use Humira 
Kako uporabljati zdravilo Humira
Check the expiry (EXP) date. 
Preverite rok uporabnosti (EXP).
The European Medicines Agency has deferred the obligation to submit the results of the studies with Humira in one or more subsets of the paediatric population in ulcerative colitis, see section 4.2 for information on paediatric use. 
Evropska agencija za zdravila je začasno odložila zahtevo za predložitev rezultatov študij z zdravilom Humira za eno ali več podskupin pediatrične populacije z ulceroznim kolitisom, za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2.
Some patients who have been successfully treated for active tuberculosis have redeveloped tuberculosis while being treated with Humira. 
Nekaterim bolnikom, ki so bili uspešno zdravljeni zaradi aktivne tuberkuloze, se je med zdravljenjem z zdravilom Humira ponovno razvila tuberkuloza.
P value* 
P vrednost*
For more information on vaccines see the “Warnings and precautions” section. 
Za več informacij o cepljenju glejte poglavje "Opozorila in previdnostni ukrepi".
Concomitant corticosteroids may be tapered in accordance with clinical practice starting two weeks after initiating treatment with Humira. 
Kortikosteroide, ki se jih daje sočasno, se lahko postopoma ukinja v skladu s klinično prakso, z začetkom dva tedna po začetku zdravljenja z zdravilom Humira.
If an anaphylactic reaction or other serious allergic reaction occurs, administration of Humira should be discontinued immediately and appropriate therapy initiated. 
Če se pojavi anafilaktična reakcija ali kakšna druga resna alergijska reakcija, je treba uporabo zdravila Humira nemudoma prekiniti in uvesti ustrezno zdravljenje.
You should record the date when the syringe is first removed from refrigerator and the date after which it should be discarded. 
Zapisati si morate datum, ko je bila brizga vzeta iz hladilnika in datum, po katerem jo je potrebno zavreči.
Radiographs of hands, wrists, and feet were obtained at baseline and Week 24 during the double-blind period when patients were on Humira or placebo and at Week 48 when all patients were on open-label Humira. 
Rentgenske posnetke dlani, zapestij in stopal so naredili izhodiščno in 24. teden med dvojno slepim obdobjem, med katerim so bolniki dobivali zdravilo Humira ali placebo, in 48. teden, ko so vsi bolniki odprto dobivali zdravilo Humira.
Other serious infections seen in clinical trials include pneumonia, pyelonephritis, septic arthritis and septicaemia. 
Med resnimi okužbami, zabeleženimi v kliničnih preskušanjih, so bile pljučnica, pielonefritis, septični artritis in septikemija.
Humira can also be used to treat severe, active and progressive rheumatoid arthritis without previous methotrexate treatment. 
Zdravilo Humira je mogoče uporabljati tudi za zdravljenje hudega, aktivnega in napredujočega revmatoidnega artritisa brez predhodnega zdravljenja z metotreksatom.
Instructions for preparing and giving an injection of Humira 
Navodila za pripravo in injiciranje zdravila Humira
The efficacy and safety of Humira were assessed in five randomised, double-blind and well-controlled studies. 
Učinkovitost in varnost zdravila Humira so ocenili v petih randomiziranih, dvojno slepih in dobro kontroliranih študijah.
Ankylosing Spondylitis Disease Activity Score Partial flare is defined as ASDAS ≥ 1.3 but < 2.1 at 2 consecutive visits. 
Activity Score) d Delni zagon bolezni je določen kot ASDAS ≥ 1,3 vendar < 2,1 pri dveh zaporednih obiskih.
Patients receiving MTX who achieved a PASI 50 response at Week 8 and/or 12 did not receive further dose increases. 
Bolnikom, ki so dobivali metotreksat in so 8. in/ali 12. teden dosegli odziv PASI ≥ 50, odmerka niso več povečevali.
• Hold the syringe in one hand and with the other hand slide the outer protective shield over the exposed needle until it locks in place 
• Z eno roko držite brizgo, z drugo pa potegnite zunanji ščitnik čez razgaljeno iglo, dokler se ne zaskoči.
Do not press the plum activator button until you are ready to inject. 
Ne pritiskajte škrlatnega sprožilnega gumba, dokler niste pripravljeni za injiciranje.
PASI 75 and PGA clear or minimal increased with increasing adalimumab concentrations, both with a similar apparent EC50 of approximately 4.5 μg/mL (95% CI 0.4-47.6 and 1.9-10.5, respectively). 
PGA čisto ali minimalno, sta se povečevali z zvečanjem koncentracije adalimumaba, obe s podobno navidezno EC50, za približno 4,5 μg/ml (95% IZ 0,4-47,6 in 1,9-10,5).
In adult plaque psoriasis patients on long term adalimumab monotherapy who participated in a withdrawal and retreatment study, the rate of antibodies to adalimumab after retreatment (11 of 482 subjects, 2.3%) was similar to the rate observed prior to withdrawal (11 of 590 subjects, 1.9%). 
Pri odraslih bolnikih s psoriazo v plakih, ki so prejemali dolgotrajno monoterapijo z adalimumabom in so sodelovali v študiji prenehanja uporabe in ponovnega zdravljenja, je bil delež protiteles proti adalimumabu po ponovnem zdravljenju (11 od 482 bolnikov; 2,3 %) podoben kot pred prenehanjem uporabe (11 od 590 bolnikov; 1,9 %).
Cases of worsening congestive heart failure have also been reported in patients receiving Humira. 
O primerih poslabšanja kongestivnega srčnega popuščanja so poročali tudi pri bolnikih, ki so prejemali zdravilo Humira.
Injection site pain of Humira 40 mg/0.4 ml was assessed in two randomised, active control, single-blind, two-period crossover studies. 
Bolečina na mestu injiciranja zdravila Humira 40 mg/0,4 ml je bila ocenjena v dveh randomiziranih enojno slepih navzkrižnih študijah z aktivnim nadzorom, v dveh obdobjih.
• Humira should only be used during a pregnancy if needed. 
• Zdravilo Humira se med nosečnostjo lahko uporablja samo, če je potrebno.
Psoriasis Study II (CHAMPION) compared the efficacy and safety of Humira versus methotrexate and placebo in 271 patients. 
Študija pri psoriazi II (CHAMPION) je primerjala učinkovitost in varnost zdravila Humira z metotreksatom in placebom pri 271 bolnikih.
Patients should be tested for HBV infection before initiating treatment with Humira. 
Bolnike je treba pred začetkom zdravljenja z zdravilom Humira testirati na okužbo s HBV.
You should record the date when the pen is first removed from refrigerator and the date after which it should be discarded. 
Zapisati si morate datum, ko je bil peresnik vzet iz hladilnika in datum, po katerem ga je potrebno zavreči.
• vertigo (feeling of dizziness or spinning) 
• vertigo (občutek omotice ali vrtenja)
• Throw away all other used items into your regular household waste. 
• Zavrzite vse ostale enote zdravila v običajen koš za odpadke.
Take one dose tray containing a pre-filled pen of Humira from the refrigerator. 
Vzemite enoodmerni ovitek z napolnjenim injekcijskim peresnikom zdravila Humira iz hladilnika.
Patients induced with 160/80 mg Humira achieved clinical remission versus placebo at Week 8 in statistically significantly greater percentages in study UC-I (18% vs. 9% respectively, p=0.031) and study UC-II (17% vs. 9% respectively, p=0.019). 
Bolniki, ki so za indukcijo dobili 160/80 mg zdravila Humira, so 8. teden v primerjavi s placebom dosegli klinično remisijo v statistično značilno večjem odstotku tako v študiji UC-I (18 % v primerjavi z 9 %, p = 0,031) kot v študiji UC-II (17 % v primerjavi z 9 %, p = 0,019).
When the injection is completed, slowly pull the pre-filled pen from the skin. 
Ko je injiciranje zaključeno, počasi odstranite napolnjen injekcijski peresnik s kože.
Hold the pre-filled syringe in one hand between the finger grip and the needle cover. 
Napolnjeno injekcijsko brizgo držite v eni roki med držalom za prste in pokrovčom igle.
Patients from studies UC-I and UC-II had the option to roll over into an open-label long-term extension study (UC III). 
Bolniki iz študij UC-I in UC-II so imeli možnost nadaljevati v odprti, dolgoročni podaljšani študiji
• Remove one box containing, one syringe, one vial adapter, one vial, two alcohol pads and one needle from the carton. 
• Odprite eno škatlo, ki vsebuje eno brizgo, en adapter za vialo, dva alkoholna zloženca in eno iglo.
If you have COPD, or are a heavy smoker, you should discuss with your doctor whether treatment with a TNF blocker is appropriate for you. 
Če imate KOPB ali če veliko kadite, se morate z zdravnikom posvetovati, ali je zdravljenje z zaviralcem TNF za vas primerno.
Mood alterations (including depression), anxiety, insomnia 
Psihiatrične motnje pogosti spremembe razpoloženja (vključno z depresijo), anksioznost, nespečnost
• Make sure the liquid is clear and colourless 
• Prepričajte se, da je tekočina bistra in brezbarvna
Polyarticular juvenile idiopathic arthritis is an inflammatory disease of the jointsthat usually first appears in childhood. 
Poliartikularni juvenilni idiopatski artritis je vnetna bolezen sklepov, ki se običajno prvič pojavi v otroštvu.
confidence interval) 
(95 % interval zaupanja)
Once removed from the refrigerator for room temperature storage, the syringe must be used within 14 days or discarded, even if it is returned to the refrigerator. 
Ko ga enkrat, namesto v hladilniku, shranjujete pri sobni temperaturi, morate peresnik porabiti v 14 dneh ali pa zavreči, tudi če ga vrnete v hladilnik.
Some patients who have not responded by Week 4 may benefit from continued maintenance therapy through Week 12. 
Nekaterim bolnikom, ki se ne odzovejo do 4. tedna, lahko koristi nadaljnje vzdrževalno zdravljenje do 12. tedna.
A patient who requires surgery while on Humira should be closely monitored for infections, and appropriate actions should be taken. 
Bolnika, ki med zdravljenjem z zdravilom Humira potrebuje operacijo, je treba natančno nadzirati glede okužb in ustrezno ukrepati.
If your child has COPD, or is a heavy smoker, you should discuss with your doctor whether treatment with a TNF blocker is appropriate for your child. 
Če ima vaš otrok KOPB ali če veliko kadi, se morate z zdravnikom posvetovati, ali je zdravljenje z zaviralcem TNF za vašega otroka primerno.
During treatment with Humira, other concomitant therapies (e.g., corticosteroids and/or immunomodulatory agents) should be optimised. 
Med zdravljenjem z zdravilom Humira je treba optimizirati druge sočasne terapije (npr. kortikosteroide in/ali imunomodulacijska zdravila).
If latent tuberculosis is diagnosed, appropriate treatment must be started with anti-tuberculosis prophylaxis treatment before the initiation of Humira, and in accordance with local recommendations. 
Če ugotovite latentno tuberkulozo, morate pred uvedbo zdravila Humira začeti s protituberkuloznim profilaktičnim zdravljenjem v skladu z lokalnimi priporočili.
The adjusted OR (accounting for baseline differences) was 1.10 (95% CI 0.45-2.73) with RA and CD combined. 
Prilagojeno razmerje obetov (z ozirom na izhodiščne razlike) je bilo 1.10 (95 % interval zaupanja 0.45-2.73) z RA in CB skupaj.
ASDAS Inactive Disease hs-CRP 
ASDAS neaktivna bolezen hs-CRPd,f,g
Humira is available in other strengths and presentations. 
Zdravilo Humira je na voljo v drugih jakostih in oblikah.
Among patients who were not in response at Week 4, 43% of Humira maintenance patients responded by Week 12 compared to 30% of placebo maintenance patients. 
Med bolniki, ki se v 4. tednu niso odzvali, se je 43 % bolnikov na vzdrževalnem odmerku zdravila Humira odzvalo do 12. tedna, v primerjavi s 30 % bolnikov na placebu.
Despite prophylactic treatment for tuberculosis, cases of reactivated tuberculosis have occurred in patients treated with Humira. 
Kljub profilaktičnemu zdravljenju za tuberkulozo, so se pri bolnikih, zdravljenih z zdravilom Humira, pojavili primeri reaktivacije tuberkuloze.
b 50 Week 2 Week 12 Week 24 ***,** Statistically significant at p < 0.001, < 0.01 for all comparisons between Humira and placebo at Weeks 2, 12 and 24 Assessments in Ankylosing Spondylitis Bath Ankylosing Spondylitis Disease Activity Index 
BASDAIb 50 2. teden 12. teden 24. teden ***,** Statistično značilno pri p < 0,001, < 0,01 za vse primerjave med zdravilom Humira in placebom po 2, 12 in 24 tednih a Ocene pri ankilozirajočem spondilitisu (Assessments in Ankylosing Spondylitis) b Bathov indeks bolezenske aktivnosti ankilozirajočega spondilitisa (Bath Ankylosing